Literature DB >> 1942006

Early SIV encephalopathy.

B Hurtrel1, L Chakrabarti, M Hurtrel, M A Maire, D Dormont, L Montagnier.   

Abstract

SIV encephalopathy was studied in rhesus macaques early after intracerebral (IC) or intravenous (IV) inoculation. Although SIV was detected in the brain of all IC-inoculated animals, the CNS showed moderate neuropathological changes. IV-inoculated animals presented a spectrum of brain changes ranging from perivascular infiltrates to multinucleated giant cells. CNS infection was detected as early as seven days post-IV-inoculation, mostly in a perivascular localization. Using combined immunohistochemistry and in situ hybridization, infected cells were shown to express macrophage markers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1942006

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  23 in total

Review 1.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

2.  Expression of inflammatory cytokines and inducible nitric oxide synthase in brains of SIV-infected rhesus monkeys: applications to HIV-induced central nervous system disease.

Authors:  T E Lane; M J Buchmeier; D D Watry; H S Fox
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

3.  Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.

Authors:  Lakshmanan Annamalai; Veena Bhaskar; Douglas R Pauley; Heather Knight; Kenneth Williams; Margaret Lentz; Eva Ratai; Susan V Westmoreland; R Gilberto González; Shawn P O'Neil
Journal:  Am J Pathol       Date:  2010-07-01       Impact factor: 4.307

4.  Cerebrospinal fluid is an efficient route for establishing brain infection with feline immunodeficiency virus and transfering infectious virus to the periphery.

Authors:  Pinghuang Liu; Lola C Hudson; Mary B Tompkins; Thomas W Vahlenkamp; Brenda Colby; Cyndi Rundle; Rick B Meeker
Journal:  J Neurovirol       Date:  2006-08       Impact factor: 2.643

5.  Enhanced expression of proinflammatory cytokines in the central nervous system is associated with neuroinvasion by simian immunodeficiency virus and the development of encephalitis.

Authors:  Marlene S Orandle; Andrew G MacLean; Vito G Sasseville; Xavier Alvarez; Andrew A Lackner
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Neuropathology associated with feline immunodeficiency virus infection highlights prominent lymphocyte trafficking through both the blood-brain and blood-choroid plexus barriers.

Authors:  Gavin Ryan; Terence Grimes; Brenda Brankin; Mohamad J E M F Mabruk; Margaret J Hosie; Oswald Jarrett; John J Callanan
Journal:  J Neurovirol       Date:  2005-08       Impact factor: 2.643

Review 7.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

8.  Identification of T lymphocytes in simian immunodeficiency virus encephalitis: distribution of CD8+ T cells in association with central nervous system vessels and virus.

Authors:  Woong-Ki Kim; Sarah Corey; Gillian Chesney; Heather Knight; Sherry Klumpp; Christian Wüthrich; Norman Letvin; Igor Koralnik; Andrew Lackner; Ronald Veasey; Kenneth Williams
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

9.  Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells.

Authors:  L Chakrabarti; P Isola; M C Cumont; M A Claessens-Maire; M Hurtrel; L Montagnier; B Hurtrel
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

Review 10.  Monocyte/macrophages and their role in HIV neuropathogenesis.

Authors:  Tricia H Burdo; Andrew Lackner; Kenneth C Williams
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.